Virios Therapeutics (VIRI) to Release Quarterly Earnings on Tuesday

Virios Therapeutics (NASDAQ:VIRI – Get Rating) will be releasing its earnings data before the market opens on Tuesday, March 14th. Analysts expect Virios Therapeutics to post earnings of ($0.16) per share for the quarter.

Virios Therapeutics Stock Down 3.9 %

Shares of Virios Therapeutics stock opened at $0.33 on Friday. The firm has a market cap of $2.72 million, a PE ratio of -0.19 and a beta of 1.84. Virios Therapeutics has a 52 week low of $0.22 and a 52 week high of $9.11. The business’s fifty day simple moving average is $0.31 and its 200-day simple moving average is $1.19.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. boosted its position in shares of Virios Therapeutics by 576.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 109,196 shares of the company’s stock worth $26,000 after purchasing an additional 93,050 shares during the period. State Street Corp acquired a new position in Virios Therapeutics in the 2nd quarter valued at about $45,000. Renaissance Technologies LLC grew its holdings in shares of Virios Therapeutics by 33.3% in the fourth quarter. Renaissance Technologies LLC now owns 235,400 shares of the company’s stock valued at $56,000 after purchasing an additional 58,800 shares in the last quarter. UBS Group AG boosted its position in Virios Therapeutics by 528.3% in the 1st quarter. UBS Group AG now owns 14,137 shares of the company’s stock valued at $63,000 after buying an additional 11,887 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Virios Therapeutics by 63.4% during the first quarter. Vanguard Group Inc. now owns 241,666 shares of the company’s stock worth $1,082,000 after acquiring an additional 93,800 shares during the period. Hedge funds and other institutional investors own 13.63% of the company’s stock.

About Virios Therapeutics

(Get Rating)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.